ABEONA THERAPEUTICS INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.8M | — | $3.5M | $1.4M | $3.0M |
| Cost of revenue | $1.5M | — | — | — | — |
| Selling, general & administrative | $65.0M | $29.9M | — | — | — |
| Research and development | $26.8M | $34.4M | $31.1M | $29.0M | $38.7M |
| Operating expenses | — | $64.2M | $50.6M | $52.3M | $92.8M |
| Operating income | -$89.4M | -$64.2M | -$47.1M | -$50.9M | -$89.8M |
| Interest expense | $3.7M | $4.2M | $418,000 | $736,000 | $3.7M |
| Pretax income | $71.3M | -$63.7M | — | — | — |
| Income tax expense | $100,000 | — | — | — | — |
| Net income | $71.2M | -$63.7M | -$54.2M | -$39.7M | -$84.9M |
| Balance Sheet | |||||
| Cash and equivalents | $78.4M | $23.4M | $14.5M | $14.2M | $32.9M |
| Current assets | $204.9M | $100.9M | $55.7M | $53.1M | $56.3M |
| Total assets | $219.6M | $108.9M | $64.0M | $64.2M | $79.6M |
| Current liabilities | $29.6M | $16.6M | $13.4M | $7.8M | $16.6M |
| Total liabilities | $60.4M | $64.9M | $49.2M | $37.5M | $37.2M |
| Total debt | $20.0M | $20.0M | — | — | — |
| Stockholders' equity | $159.2M | $44.0M | $14.8M | $26.8M | $42.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$76.3M | -$56.0M | -$37.0M | -$43.5M | -$65.7M |
| Depreciation and amortization | $2.5M | $2.0M | $2.3M | $3.1M | $3.2M |
| Stock-based compensation | $10.8M | $6.6M | $4.8M | $3.1M | $8.9M |
| Capital expenditure | $8.0M | $2.4M | $331,000 | $130,000 | $4.2M |
| Free cash flow | -$84.3M | -$58.5M | -$37.3M | -$43.6M | -$69.8M |
| Share repurchases | — | — | — | $25.0M | — |
| Impairments | — | — | — | $1.8M | $32.5M |
Shares outstanding 57.0M · Free float 61.0%
Annual filing data through FY ended December 31, 2025; float as of July 8, 2026.